Indoco Remedies Ltd. (NSE: INDOCO, BSE: 532612) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,026 Cr, it ranks #1,235 by market cap among the 6,197 Indian listed companies on FinBizNet, and #36 of 86 in Medicinal Chemicals and Botanical Products. At ₹227.30 (as of 16 Nov 2026), the share price is 21.0% below its 52-week high of ₹287.80 and 40.1% above its 52-week low of ₹162.19. The share price is down 12.4% over one year and up 2.9% over three months.
| Current Price | ₹227.30 |
|---|---|
| Market Cap | ₹2,026 Cr |
| NSE Symbol | INDOCO |
| BSE Code | 532612 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -10.12% |
| Return on Assets | 0.40% |
| 52-Week Range | ₹162.19 – ₹287.80 |
| 1-Year Price Change | -12.4% |
| 3-Month Price Change | +2.9% |
| Beta (1Y) | 0.36 |
| Dividend Yield | 0.09% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.indoco.com |
| Revenue | ₹520 Cr |
|---|---|
| Net Profit | ₹19 Cr |
| Net Margin | 3.7% |
| EPS (Basic) | ₹2.11 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Indoco Remedies Ltd. reported revenue of ₹520 Cr in Q2 FY27, up 7.3% from ₹485 Cr in Q2 FY26 and up 11.3% from ₹468 Cr in Q1 FY27. It posted a net profit of ₹19 Cr for the quarter, against a net loss of ₹9 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹390 Cr (Q4 FY25) to ₹520 Cr (Q2 FY27). The company reported a net loss in 5 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹520 Cr | ₹19 Cr | 3.7% |
| Q1 FY27 | ₹468 Cr | ₹65 Cr | 14.0% |
| Q4 FY26 | ₹476 Cr | −₹24 Cr | −5.0% |
| Q3 FY26 | ₹445 Cr | −₹29 Cr | −6.6% |
| Q2 FY26 | ₹485 Cr | −₹9 Cr | −1.9% |
| Q1 FY26 | ₹438 Cr | −₹36 Cr | −8.3% |
| Q4 FY25 | ₹390 Cr | −₹41 Cr | −10.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 58.92% of Indoco Remedies Ltd.'s shares as of Sept 2026, against 58.90% in Sept 2025 (+0.02 percentage points). Delivery averaged 45.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and valid
1. Pharmaceuticals-This segment manufactures and sells formulations and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Indoco Remedies Ltd. | ₹2,026 Cr | n/m | -10.12% | ₹520 Cr | -12.4% |
Listed by market capitalisation. Ratios are shown for context only.
Indoco Remedies Ltd. is trading at ₹227.30, with a market capitalisation of ₹2,026 Cr.
Indoco Remedies Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Indoco Remedies Ltd. has a return on equity of -10.12%.
Indoco Remedies Ltd. is listed on the NSE under the symbol INDOCO and on the BSE under the scrip code 532612.
Indoco Remedies Ltd.'s share price is down 12.4% over one year and up 2.9% over three months. Its 52-week range is ₹162.19 to ₹287.80.
In Q2 FY27, Indoco Remedies Ltd. reported revenue of ₹520 Cr and net profit of ₹19 Cr, with basic EPS of ₹2.11 (consolidated, parsed from the company's exchange filing).
Indoco Remedies Ltd. reported revenue of ₹520 Cr in Q2 FY27, up 7.3% from ₹485 Cr in Q2 FY26 and up 11.3% from ₹468 Cr in Q1 FY27.
Promoters held 58.92% of Indoco Remedies Ltd.'s shares as of Sept 2026, against 58.90% in Sept 2025 (+0.02 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.